RIA
SRPT icon

Realta Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Realta Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-425
Closed -$64K – 1782
2019
Q2 		$64K Buy
425
+155
+57% +$18.8K 0.02% 619
2019
Q1 		$32K Buy
+270
New +$34.7K 0.01% 660

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Realta Investment Advisors's SRPT Position: Q3 2019 in Review

Realta Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 425 shares — an estimated $64K sold.

Realta Investment Advisors first reported a position in SRPT in Q1 2019 and held it in 2 quarters. The position peaked at $64K in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Realta Investment Advisors reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Realta Investment Advisors sold 425 Sarepta Therapeutics shares in Q3 2019, an estimated $64K.
  • Realta Investment Advisors first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 2 quarters.
  • Realta Investment Advisors's Sarepta Therapeutics position peaked at $64K in Q2 2019.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Realta Investment Advisors's 13F filing for Q3 2019, filed 18 Oct 2019.